乳腺癌预后生物标志物研究进展  

Research advances in biomarkers of the prognosis of breast cancer

作　　者：韩璐[1] 宋丰举[1] 陈可欣[1] 

机构地区：[1]天津医科大学肿瘤医院国家肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室肿瘤分子流行病与生物统计研究室,300060

出　　处：《天津医药》2016年第4期404-407,共4页Tianjin Medical Journal

基　　金：国家自然科学基金资助项目(81473039;81172762)

摘　　要：乳腺癌是世界范围内女性发病率最高的恶性肿瘤,也是导致女性癌症相关死亡的最主要原因。近些年乳腺癌患者数量呈逐年增加趋势,严重威胁女性的生命健康和生活质量。因此,乳腺癌预后的研究对乳腺癌患者意义深远。随着分子生物学的发展,一些分子生物学标志物被发现与乳腺癌患者预后有关,这使得更准确、有效地评估乳腺癌患者的预后成为可能。本文旨在对乳腺癌预后生物标志物的研究进展作一综述。Breast cancer has become the most common malignant tumor and the major cause of cancer-related death forwomen around the world. The number of patients shows an increasing trend recently. Breast cancer is a big threaten to wom-en＇s health and quality of life. With the development of molecular biology, molecular biomarkers have been found assiciatedwith prognosis in patients with breast cancer, which makes it possible to predict cancer patient survival precisely and practi-cally. This review summarized those new developments of biomarkers on the prognosis of breast cancer.

关 键 词：乳腺肿瘤 预后 生物学标记 综述 MIRNA-21 miRNA-210 CXCR4 ALDH1A1 BCL2 BRCA1/BRCA2 

分 类 号：R737.9[医药卫生—肿瘤] R342.2[医药卫生—临床医学]